奧拉替尼

給藥途徑

禁忌症

• Dogs less than 12 months of age
• Dogs weighing less than 3 kg
• Dogs with severe systemic infections
• Breeding, pregnant, or lactating dogs
• Dogs with evidence of immune suppression (e.g., hyperadrenocorticism)
• Dogs with a history of progressive malignant neoplasia

不良反應

• Gastrointestinal upset (vomiting, diarrhea, anorexia)
• Lethargy
• Increased susceptibility to infections (e.g., pyoderma, otitis, demodicosis, pneumonia)
• Transient decreases in leukocytes and serum globulins
• Potential exacerbation of neoplastic conditions
• Histiocytomas or papillomas (benign skin masses)

藥物相互作用

• Corticosteroids · Increased risk of immunosuppression and secondary infections. · major
• Cyclosporine · Increased risk of profound immunosuppression. · major
• Modified live vaccines · Potential for decreased vaccine efficacy or vaccine-induced illness due to immunomodulation. · moderate

監測

• Baseline CBC, serum biochemistry, and urinalysis
• Periodic bloodwork (e.g., every 6-12 months) for dogs on long-term therapy
• Monitor for new or worsening skin, ear, or systemic infections
• Monitor for the development of cutaneous or systemic neoplastic lesions

過量

Overdoses up to 3-5 times the therapeutic dose are generally well tolerated but may increase the frequency and severity of expected side effects, particularly **gastrointestinal distress** (vomiting, diarrhea), **lethargy**, and localized **alopecia** or skin thickening. Chronic massive overdose increases the risk of severe immunosuppression and secondary infections. Treatment is supportive and symptomatic, as there is no specific antidote.